30 November 2017

In patients who receive a modern stent after a heart attack, a three-month treatment with dual antiplatelet therapy does not lead to more complications than with the current standard treatment of twelve months.

This is shown by international research presented by Harry Suryapranata during the cardiology TCT conference in Denver, USA.
The optimal treatment duration with blood thinners after implantation of a stent in patients with acute coronary syndrome is under discussion. We are constantly looking for an optimum between the risk of clotting and bleeding. Longer treatment with the usual two dual antiplatelet therapy reduces the risk of clotting problems (new heart attack, coagulation in the stent), but at the same time increases the risk of bleeding. The current recommendation - using twelve months of dual dual antiplatelet therapy after a stent implant - is based primarily on research with older stents.
Complications equal in both groups
The REDUCE study, which was conducted in 36 hospitals in Europe and Asia, uses a new bioactive stent, which promotes the natural recovery of the vascular wall. The study, which involved nearly 1500 patients, examined the difference between twelve or three months of use of dual antiplatelet therapy in this specific stent.
"The results show that after implantation of this stent, treatment duration of three months is not worse than the usual twelve months," says Harry Suryapranata, principal investigator of the study and professor of cardiology at Radboudumc. "In about 1 in 12 patients, we experienced one of the following complications in the first year after stent implant: deaths, myocardial infarctions, stent thromboses, strokes, new procedures in the treated coronary artery or bleeding complications. Based on these criteria, we saw no difference in complications between the group that was treated for twelve or three months.'
Important contribution
In the Radboudumc the REDUCE study was conducted under the supervision of intervention cardiologist Cyril Camaro and researcher Sander Damen. Camaro: "This research shows that a shorter treatment duration with dual anti-platelet therapy can be considered when needed, even in patients who have had a heart attack." Suryapranata, who presented the results at a conference in Denver: "It is an important and remarkable finding, but larger studies must confirm this hypothesis. Also because we now have many different types of anti-platelet agents. '

Suryapranata H, De Luca G. REDUCE: A Randomized Trial of 3-Month vs 12-Month DAPT After Implantation of a Bioabsorbable Polymer-Based Metallic DES with a Luminal CD34+Antibody Coating in Patients with ACS. Late Breaking Clinical Trial at the 29th annual Transcatheter Cardiovascular Therapeutics scientific symposium, November 1, 2017.
TCT congress: https://www.tctmd.com/news/shortened-dapt-durations-appear-safe-patients-acs-implanted-des

Related news items

AI helps the defibrillator think

4 October 2021 In the future, the AED and the defibrillator will be able to do more than they do today. Now the devices can only give patients who need to be resuscitated a shock, but in time it will be possible, with the help of artificial intelligence, to say more about the condition of the patient. read more

Experts call for urgent action to reduce global burden of cardiovascular disease in women by 2030

17 May 2021 There is an urgent need to address this, states the international Lancet 'Women and Cardiovascular Disease' Commission read more

Water as a new tool for cardiac screening for chest pain

2 March 2021 Patients with chest pain not caused by a narrowing of the coronary arteries often do not know the cause of their symptoms. Scientists at the Radboudumc have successfully used a new technique to investigate other causes in the coronary arteries of the heart. read more

Pregnancy complications and early menopause affect cardiovascular disease in women

9 February 2021 A number of specific conditions in women are important in their risk of cardiovascular disease. These include high blood pressure during pregnancy, gestational diabetes and early menopause. read more

Cardiac function in relation to myocardial injury in hospitalised patients with COVID-19

16 July 2020 In Netherlands Heart Journal RIHS researcher Frederik van den Heuvel described that in hospitalized COVID-19 patients, COVID-19 predominantly affects the respiratory system, while cardiac dysfunction occurs less often. read more

More than 350 festival attendees learned CPR during the Lowlands Saves Lives trial

26 August 2019 During the 2019 Lowlands music festival, the Lowlands Saves Lives trial was performed by the department of Cardiology. The study was a huge success as over 350 participants were randomized and learned to perform CPR. read more